🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,557 results for “placebo” Clear

  1. Placebo

    BRIGHT MINDS BIOSCIENCES INC.

    D-limonene and THC Pharmacodynamics

    phase 1 small molecule completed

    1 trial

  2. Placebo

    BRIGHT MINDS BIOSCIENCES INC.

    Healthy

    phase 1 small molecule completed

    2 trials

  3. Placebo

    IONIS PHARMACEUTICALS INC

    Healthy Participants

    phase 1 small molecule completed

    1 trial

  4. Placebo

    The First People's Hospital of Lianyungang

    Asthma

    phase 1 small molecule active

    1 trial

  5. Placebo

    BRIGHT MINDS BIOSCIENCES INC.

    Memory

    phase 1 small molecule completed

    1 trial

  6. Placebo

    BRIGHT MINDS BIOSCIENCES INC.

    Methamphetamine Abuse

    phase 1 small molecule completed

    1 trial

  7. Placebo

    BRIGHT MINDS BIOSCIENCES INC.

    Methamphetamine Use Disorder

    phase 1 small molecule active

    1 trial

  8. Placebo

    BRIGHT MINDS BIOSCIENCES INC.

    THC

    phase 1 small molecule completed

    1 trial

  9. Placebo - MAD

    Hoffmann-La Roche

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  10. Placebo Aprepitant

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Withdrawal

    phase 1 small molecule completed

    1 trial

  11. Placebo Intravaginal Ring A

    United Therapeutics Europe Ltd

    Safety

    phase 1 other terminated

    1 trial

  12. Placebo Vaginal Film with Square Corners

    United Therapeutics Europe Ltd

    Safety

    phase 1 small molecule completed

    1 trial

  13. Placebo and Oxycodone

    BRIGHT MINDS BIOSCIENCES INC.

    Hypercapnia

    phase 1 small molecule completed

    1 trial

  14. Placebo for Treatment A

    Agios Netherlands B.V.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  15. Placebo for antibiotic

    Seres Therapeutics

    Metastatic Melanoma

    phase 1 small molecule completed

    1 trial

  16. Placebo gelatin pill

    Universal Integrated

    Vaginosis, Bacterial

    phase 1 small molecule completed

    1 trial

  17. Placebo oral capsule

    Biogen

    Healthy

    phase 1 small molecule completed

    1 trial

  18. Placebo pills for 14-day intervention

    BRIGHT MINDS BIOSCIENCES INC.

    Healthy Controls

    phase 1 small molecule active

    1 trial

  19. Placebo spray and oral moxifloxacin placebo

    Jazz Pharmaceuticals Ireland Limited

    Effects of Sativex on ECG

    phase 1 small molecule completed

    1 trial

  20. REGN1154 or placebo

    Regeneron UK Limited

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  21. Randomized, double-blind, placebo-controlled, two-part study assessing the safety, tolerability and pharmacokinetics of BP1.7881 administered as higher doses, after single ascending doses (Part I) and multiple ascending doses (Part II), including the assessment of BP1.7881 on cardiac repolarization, in healthy subjects.

    Bioprojet Pharma

    Eosinophilic esophagitis

    phase 1 other active

    1 trial

  22. Recombinant Humanized Anti-IL-36R Monoclonal antibody and Placebo

    Shanghai University of Traditional Chinese Medicine

    Healthy

    phase 1 small molecule completed

    1 trial

  23. SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as Placebo

    Silence Therapeutics plc

    Non-transfusion-dependent Thalassemia

    phase 1 small molecule terminated

    1 trial

  24. Safety, pharmacokinetics and pharmacodynamics study of Leucettinib-21 in healthy subjects, Down Syndrom and Alzheimer patients

    Lacuna Pharma Pty Ltd

    A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses and Food Effect of Leucettinib-21 in Healthy Male Subjects, followed by an open single dose of Leucettinib-21 in Down Syndrome individuals, and patients with Alzheimer’s disease

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources